Hot Pursuit     14-Jun-24
Lupin Nagpur unit clears USFDA inspection
The inspection concluded with zero 483 observations by the US drug regulator.

The pharma major said that its injectable facility located at Nagpur has completed the United States Food and Drug Administration (USFDA) inspection with zero observations.

The inspection of the facility was carried out from 10 June 2024 to 13 June 2024 and the USFDA concluded with zero 483 observations.

Nilesh Gupta, managing director of Lupin said, “We are pleased to have a successful outcome of the U.S. FDA inspection at our Nagpur injectable facility with zero observations. This reflects our dedication to uphold the highest quality and compliance standards across our facilities.”

Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The company’s consolidated net profit tumbled 41.38% to Rs 359.43 crore on 3.64% decline in revenue from operations to Rs 4,895.11 crore in Q4 FY24 over Q4 FY23.

The scrip shed 0.05% to Rs 1,604.55 on the BSE.

Previous News
  Lupin divests its U.S. Commercial Women's Health Specialty Business
 ( Corporate News - 15-Jul-24   17:55 )
  Lupin receives EIR from USFDA for Dabhasa facility
 ( Hot Pursuit - 13-Jul-24   16:48 )
  Lupin schedules AGM
 ( Corporate News - 10-Jul-24   17:25 )
  Lupin allots 42,932 equity shares under ESOP
 ( Corporate News - 09-Jul-24   15:16 )
  Lupin fixes record date for dividend
 ( Market Beat - Reports 04-Jul-24   15:27 )
  Market hits fresh life highs; Nifty ends above 24,000 level
 ( Market Commentary - The Week That Was 28-Jun-24   16:33 )
  Lupin to pay fine of Euro 40 million to European Commission
 ( Corporate News - 28-Jun-24   09:08 )
  Lupin gains on receiving EIR from USFDA for New Jersey facility
 ( Hot Pursuit - 24-Jun-24   10:32 )
  Lupin allots 43,475 equity shares under ESOP
 ( Corporate News - 21-Jun-24   12:12 )
  Lupin Ltd slips for fifth straight session
 ( Hot Pursuit - 18-Jun-24   13:35 )
  Lupin appoints Abdelaziz Toumi as CEO of API CDMO arm
 ( Hot Pursuit - 17-Jun-24   12:28 )
Other Stories
  JSW Energy PAT soars 80% YoY to Rs 522 crore in Q1 FY25
  20-Jul-24   17:15
  Yes Bank Q1 PAT climbs 47% YoY to Rs 502 crore
  20-Jul-24   16:46
  Patanjali Foods Q1 PAT soars 3-fold to Rs 263 cr
  20-Jul-24   16:08
  Nippon Life Q1 PAT surges 40% YoY to Rs 332 cr
  20-Jul-24   15:44
  HDFC Bank Q1 PAT grows 35% YoY to Rs 16,175 crore
  20-Jul-24   15:31
  Kotak Mahindra Bank Q1 PAT zooms 81% YoY to Rs 6,250 cr
  20-Jul-24   15:13
  JSW Steel Q1 PAT drops 64% YoY to Rs 867 crore
  20-Jul-24   13:39
  ICICI Lombard Q1 PAT climbs 49% YoY to Rs 580 cr
  20-Jul-24   12:14
  Oberoi Realty Q1 PAT soars 82% YoY to Rs 584 cr
  20-Jul-24   11:16
  RIL PAT slides 4% YoY to Rs 17,448 crore in Q1 FY25
  20-Jul-24   10:33
Back Top